CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma, today appointed Brian Hess as Interim Chief Science Officer. Mr. Hess, a former Stryker biomaterials product development specialist, joined InVivo as its Director of Product Development in February 2012. As Director of Product Development, Mr. Hess is responsible for managing, developing and maintaining the pipeline for the entire portfolio of InVivo products. Mr. Hess replaces Edward Wirth, MD, PhD, who has resigned from his position as Chief Science Officer for personal reasons.
